MITA Says Medicare Coverage Decision for Low-Dose CT Scans to Detect Lung Cancer is a Win for Patients


Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) today issued the following statement in response to the Centers for Medicare & Medicaid Services’ (CMS) final decision to cover annual low-dose computed tomography (LDCT) scans for Medicare beneficiaries who are at high risk for lung cancer:

“This decision is a triumph for Medicare beneficiaries who are at high-risk for lung cancer and will now have access to life-saving scans,” said Gail Rodriguez, executive director of MITA. “Given the high bar CMS holds in making national coverage determinations, it is clear that the benefits of LDCT scans for those at high risk of lung cancer are indisputable. This decision comes at an important time in the battle against this devastating disease, as the American Cancer Society recently reported that lung cancer has overcome breast cancer as the number one killer of women in developed countries. Expanding access to this early detection tool is a step in the right direction.”


The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers, innovators and product developers. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging technology and radiation therapy. For more information, visit Follow MITA on Twitter @MITAToday.